MCF7/182R-6

General description

Oestrogen receptor only. Upon withdrawal of fulvestrant, the resistant phenotype is stable and the cells express ER alpha, although at a reduced level. The MCF7/182R-6 cells do not express progesterone receptor. The MCF7/182R-6 cells express increased level of EGFR, phosphorylated EGFR and phosphorylated ErbB3 and reduced level of ErbB4 compared to the parental MCF7/S0.5 cells

Cell Line Description

The MCF7/182R-6 Cell line is a breast cancer cell line resistant to fulvestrant. The MCF7/182R-6 cell line has been established from a clone of MCF7/S0.5 cells surviving long term growth with the pure steroidal antiestrogen ICI 182,780 in 100 nM concentration, see Lykkesfeldt et al (1995). The MCF7/182R-6 cells are grown in the presence of fulvestrant.

Culture Medium

Phenol red free DMEM:F12 (1:1) (D6434) + 1% FBS (F2442), 2.5 mM Ala-Gln (G8541) and 6 ng/ml insulin. Supplemented with 100nM fulvestrant to maintain resistance.

Subculture Routine

Split sub-confluent cultures (70-80%) 1:3 to 1:6 i.e. seeding at 2-4 x 10, 000 cells/cm² using 0.05% trypsin or trypsin or trypsin/EDTA; 5% CO₂; 37°C.

Other Notes

Cultures from PHE Culture Collections and supplied by Sigma are for research purposes only. Enquiries regarding the commercial use of a cell line are referred to the depositor of the cell line. Some cell lines have additional special release conditions such as the requirement for a material transfer agreement to be completed by the potential recipient prior to the supply of the cell line. Please view the Terms & Conditions of Supply for more information.

Citation

If use of this culture results in a scientific publication, it should be cited in the publication as: MCF7/182R-6 (ECACC 16022506)

Disclaimer

This cell line has special release conditions: Commercial organisations are required to complete the ′Cell Line Release Authorisation for Research Use in Commercial Organisations′ release conditions form.